Novel PCNT variants in MOPDII with attenuated growth restriction and pachygyria. Issue 3 (7th July 2020)

• Record Type: Journal Article
• Authors: Waich, Stephanie; Janecke, Andreas R.; Parson, Walther; Greber‐Platzer, Susanne; Müller, Thomas; Huber, Lukas A.; Valovka, Taras; Vodopiutz, Julia
• Is Part Of: Clinical genetics. Volume 98:Issue 3(2020)
• Page Start: 282
• Page End: 287
• Publication Date: 2020-07-07
• Subjects: microcephalic osteodysplastic primordial dwarfism type II -- MOPDII -- normal mitotic morphology -- pachygyria -- pericentrin; Medical genetics -- Periodicals; 616.0420
• DOI: 10.1111/cge.13797
• Languages: English
• ISSNs: 0009-9163

Abstract

Abstract: Biallelic loss‐of‐function mutations in the centrosomal pericentrin gene ( PCNT ) cause microcephalic osteodysplastic primordial dwarfism type II (MOPDII), which is characterized by extreme growth retardation, microcephaly, skeletal dysplasia, and dental anomalies. Life expectancy is reduced due to a high risk of cerebral vascular anomalies. Here, we report two siblings with MOPDII and attenuated growth restriction, and pachygyria. Compound heterozygosity for two novel truncated PCNT variants was identified. Both truncated PCNT proteins were expressed in patient's fibroblasts, with a reduced total protein amount compared to control. Patient's fibroblasts showed impaired cell cycle progression. As a novel finding, 20% of patient's fibroblasts were shown to express PCNT comparable to control. This was associated with normal mitotic morphology and normal co‐localization of mutated PCNT with centrosome‐associated proteins γ‐tubulin and centrin 3, suggesting some residual function of truncated PCNT proteins. These data expand the clinical and molecular spectrum of MOPDII and indicate that residual PCNT function might be associated with attenuated growth restriction in MOPDII. Abstract :